What comes after a successful M&A hunt at Gilead Sciences? A promotion for the executive who sewed up its $11.9 billion deal for Kite Pharma.
Reckitt Benckiser’s feelings about Pfizer’s OTC unit haven’t changed since the company said it’d be keen to buy it. But its resources have.
Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.
Novartis has decided not to sell its $14 billion Roche stake, but that doesn't mean its strategic revamp is over.
Shortages of drugs produced in Puerto Rico are beginning to materialize after hurricanes Irma and Maria wreaked havoc on production on the island.
Pfizer, which put Big Pharma split-offs in vogue back in 2012, is at it again, this time with a potential sale or spinoff in consumer health.
BDO sifted through SEC filings to discover just what the top 100 life sciences companies are most worried about these days.
Reports have said Impax could bulk up in the face of generics pricing pressure. And at least one analyst says Endo should follow suit.
Despite megamerger deal speculation, Novartis has been pledging bolt-on deals, and the latest buzz says it has a $2.6 billion target in its sights.
Amid a wave of pricing pressure and consolidation in the generics industry, another sale is brewing.